Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
2012 2
2013 2
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Lyme disease in children.
Belani K, Regelmann WE. Belani K, et al. Among authors: regelmann we. Rheum Dis Clin North Am. 1989 Nov;15(4):679-90. Rheum Dis Clin North Am. 1989. PMID: 2685925 Review.
Newer diagnostic tests to detect infection during the early stage will optimize the management of Lyme disease and further decrease the incidence of long-term sequelae....
Newer diagnostic tests to detect infection during the early stage will optimize the management of Lyme disease and further decrease the inci …
Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms.
Regelmann WE, Schechter MS, Wagener JS, Morgan WJ, Pasta DJ, Elkin EP, Konstan MW; Investigators of the Epidemiologic Study of Cystic Fibrosis. Regelmann WE, et al. Pediatr Pulmonol. 2013 Jul;48(7):649-57. doi: 10.1002/ppul.22658. Epub 2012 Sep 4. Pediatr Pulmonol. 2013. PMID: 22949088 Free PMC article.
The presence of these four characteristic signs and symptoms is useful to define pulmonary exacerbations in young children with CF that respond to antibiotic treatment in the short-term and influence long-term prognosis....
The presence of these four characteristic signs and symptoms is useful to define pulmonary exacerbations in young children with CF that resp …
Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.
Wagener JS, Rasouliyan L, VanDevanter DR, Pasta DJ, Regelmann WE, Morgan WJ, Konstan MW; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Wagener JS, et al. Among authors: regelmann we. Pediatr Pulmonol. 2013 Jul;48(7):666-73. doi: 10.1002/ppul.22652. Epub 2012 Aug 8. Pediatr Pulmonol. 2013. PMID: 22888106 Free PMC article.
METHODS: We used 2003-2005 data from the Epidemiologic Study of Cystic Fibrosis to examine antibiotic treatment and the immediate and long-term lung function change associated with clinician reported PExs. ...
METHODS: We used 2003-2005 data from the Epidemiologic Study of Cystic Fibrosis to examine antibiotic treatment and the immediate and long- …
Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
Davies JC, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Robertson S, Green Y, Cooke J, Rosenfeld M; KIWI Study Group. Davies JC, et al. Among authors: regelmann we. Lancet Respir Med. 2016 Feb;4(2):107-15. doi: 10.1016/S2213-2600(15)00545-7. Epub 2016 Jan 21. Lancet Respir Med. 2016. PMID: 26803277 Free PMC article. Clinical Trial.
Participants received oral ivacaftor 50 mg (if bodyweight <14 kg) or 75 mg (if bodyweight 14 kg) every 12 h for 4 days in part A (to establish the short-term safety of doses for subsequent assessment in part B), and then for 24 weeks in part B (to assess safety and long …
Participants received oral ivacaftor 50 mg (if bodyweight <14 kg) or 75 mg (if bodyweight 14 kg) every 12 h for 4 days in part A (to esta …